San Mateo, CA, United States of America

Ali Sadra

USPTO Granted Patents = 9 


 

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 175(Granted Patents)


Company Filing History:


Years Active: 2010-2015

Loading Chart...
Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents

Title: Innovations of Ali Sadra in Cancer Treatment

Introduction

Ali Sadra is a prominent inventor based in San Mateo, California, known for his significant contributions to the field of biotechnology. He has been instrumental in developing innovative methods for treating diseases, particularly cancers and disorders related to angiogenesis. With a total of nine patents to his name, Sadra's work has the potential to impact the medical community profoundly.

Latest Patents

Among his latest patents, Ali Sadra has developed methods of treating diseases with FGFR1 fusion proteins. This invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers. The FGFR fusion molecules can be produced in CHO cells and may include deletion mutations in the extracellular domains of the FGFRs, which enhance their stability. These fusion proteins have been shown to inhibit the growth and viability of cancer cells both in vitro and in vivo. The high affinity of these receptors for their ligand FGFs, combined with the ability of these decoy receptors to inhibit tumor growth, indicates the clinical value of the compositions and methods provided.

Another significant patent involves FGFR2 fusion proteins comprising C-terminal deletion mutants of FGFR2-IIIC. Similar to his FGFR1 work, this invention also focuses on treating proliferative disorders, including cancers. The methods of making and using these fusion proteins are designed to improve stability and efficacy in inhibiting cancer cell growth.

Career Highlights

Ali Sadra is currently associated with Five Prime Therapeutics, Inc., where he continues to innovate in the field of cancer treatment. His work has garnered attention for its potential to provide new therapeutic options for patients suffering from various forms of cancer.

Collaborations

Throughout his career, Ali has collaborated with notable colleagues, including Elizabeth Bosch and Diane Hollenbaugh. These partnerships have contributed to the advancement of his research and the development of his patented technologies.

Conclusion

Ali Sadra's innovative work in developing FGFR fusion proteins represents a significant advancement in cancer treatment. His contributions to biotechnology and medicine highlight the importance of research and innovation in addressing complex health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…